Sector News

Shire plots rare disease ‘innovation hub’ in Kendall Square

November 24, 2016
Life sciences

Shire is expanding its innovation play in Cambridge, MA, as it looks to boost its presence in Kendall Square and create a 550,000-square-foot campus focused on rare diseases.

The Irish-HQ’d biopharma said it has penned a new lease with BioMed Realty for the building at the beating heart of biotech in Kendall Square and is set to take up its new digs in 2019.

Shire already has its own place just opposite and said its expanded ops “will create a cross-disciplinary Kendall Square campus, with teams spanning research, clinical development, medical affairs, business development, and other related functions.”

It hopes that scientists will rub shoulders and create some extra sparks of innovation for its rare disease pipeline.

“By expanding our presence in Cambridge, with its close proximity to best-in-class hospitals, research institutions, universities and a thriving biotechnology community, we will strengthen our ties with the early innovators around us to shape the next generation of breakthrough therapies for patients with high unmet needs,” said Shire’s CEO Flemming Ornskov.

“These plans signify our continued growth and our deep and enduring commitment to serving patients, families and caregivers across the globe who are affected by rare diseases and highly specialized conditions.”

Shire said it will retain its current office, lab, and manufacturing space in Massachusetts, as well as its site in Lexington.

The company also said that it was undertaking a “strategic review” to see who will be moving over to the digs in the coming years. It noted that it already had around 400 positions currently up for grabs in Massachusetts.

Shire hopes to have better luck than some its recent pipeline meds, as a few weeks back it quietly got rid of its rare, midstage candidate SHP610, a med that was being studied in patients with Sanfilippo syndrome type A (MPS-IIIA), after failing to hit its primary endpoint of slowing cognitive decline in patients.

By Ben Adams

Source: Fierce Biotech

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach